Dimethyl-fumarate
Fusobacterium nucleatum associated pericarditis and spondylodiscitis: case reportA 49-year-old woman developed Fusobacterium nucleatum associated pericarditis and spondylodiscitis during treatment with dimethyl fumarate for multiple sclerosis [time to reactions onsets not stated] .The woman was admitted due to chest pain and severe back pain of mechanical nature. Her pain was worse while mobilising with a visual analogue score of 10/10. Her CRP was found to be mildly increased. Her medical history was significant for multiple sclerosis, and she had been receiving dimethyl fumarate [Tecfidera] 240mg twice daily since many years [route not stated]. She had been admitted to another hospital due to severe back pain and fever, 25 days ago. Her CRP was elevated at 200 mg/L. An MRI of her lumbar spine showed an infective and inflammatory process involving the L2/L3 disc space. Thus, she received an empirically treatment with ceftriaxone and gentamicin. Eventually, an improvement was noted. A new MRI before discharge from the previous hospital demonstrated some improvement in the radiological appearance of her infective and inflammatory process. After 2 weeks of inpatient antibiotics, she was discharged with amoxicillin/clavulanic acid [co-amoxiclav]. During the current presentation, due to the chest pain and shortness of breath, she was referred to the respiratory and cardiology teams. An echocardiogram showed mild pericardial effusion (pericarditis).Then, the woman received ibuprofen. A lumbar MRI confirmed a worsening radiological picture of the L2/L3 disc space pathology and increased prevertebral collection with a CRP of 16 mg/L. A CT-guided biopsy showed optimal positioning of the needle in the involved area of the L2/L3 intervertebral disc. Further, her clinical presentation improved, and she was discharged on ibuprofen. However, after 3 weeks, she again presented with worsening back pain. Then, she was admitted to spinal unit. A new MRI scan revealed progression of the L2/L3 spondylodiscitis with bone destruction, an increased prevertebral collection and bone marrow oedema involving the majority of the L2 and L3 vertebral bodies. Her CRP was increased to 62 mg/L. Subsequently, she underwent percutaneous minimal invasive intervertebral disc biopsy at L2/L3 and washout. Later, Fusobacterium nucleatum was isolated from the sample. She was diagnosed with Fusobacterium nucleatum associated spondylodiscitis. She was treated with clindamycin and metronidazole. Reportedly, she had a history periodontitis and dental cleaning 4-5 weeks before the onset of the back pain. After the surgery, her pain improved and CRP decreased. At 2 weeks post operatively, she was back to normal. She was discharged on unspecified antibacterials [antibiotics]. Eventually, her symptoms improved with no back pain. A follow-up MRI at the end of the 1 year demonstrated an excellent resolution of the infection with only a minimal residual marrow oedema. She was asymptomatic and discharged from the spinal team.